Last €0.80 EUR
Change Today +0.077 / 10.69%
Volume 3.1K
LX3 On Other Exchanges
Symbol
Exchange
LX3 is not on other exchanges.
As of 12:08 PM 11/24/14 All times are local (Market data is delayed by at least 15 minutes).

lexicon pharmaceuticals inc (LX3) Snapshot

Open
€0.78
Previous Close
€0.72
Day High
€0.80
Day Low
€0.75
52 Week High
12/2/13 - €1.73
52 Week Low
11/21/14 - €0.72
Market Cap
568.9M
Average Volume 10 Days
1.1K
EPS TTM
--
Shares Outstanding
713.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LEXICON PHARMACEUTICALS INC (LX3)

Related News

No related news articles were found.

lexicon pharmaceuticals inc (LX3) Related Businessweek News

No Related Businessweek News Found

lexicon pharmaceuticals inc (LX3) Details

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for human disease. Its drug development programs include LX4211, an orally-delivered small molecule compound that has completed two Phase II clinical trials for the treatment of type 2 diabetes patients, as well as an additional clinical trial for the treatment of type 2 diabetes patients with renal impairment; and completing a Phase II clinical trial for the treatment of type 1 diabetes patients. The company also develops telotristat etiprate or LX1032, an orally-delivered small molecule drug candidate, which has completed two Phase II clinical trials and is in a pivotal Phase III clinical trial for the treatment of carcinoid syndrome and ulcerative colitis. In addition, it develops LX1033, an orally-delivered small molecule compound that has completed Phase II clinical trial for the treatment of irritable bowel syndrome; LX2931, an orally-delivered small molecule compound, which has completed Phase II clinical trial for the treatment of rheumatoid arthritis; and LX7101, a topically-delivered small molecule compound that has completed Phase 1 clinical trial for the treatment of glaucoma. Further, the company’s preclinical development programs comprise LX2761, an orally-delivered small molecule compound for the treatment of diabetes. It has drug discovery and development collaborations with Bristol-Myers Squibb Company, Genentech, Inc., and Takeda Pharmaceutical Company Limited. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

149 Employees
Last Reported Date: 03/7/14
Founded in 1995

lexicon pharmaceuticals inc (LX3) Top Compensated Officers

Co-Founder, Chief Scientific Officer and Exec...
Total Annual Compensation: $406.7K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $391.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $370.0K
Executive Vice President of Pharmaceutical Re...
Total Annual Compensation: $355.8K
Compensation as of Fiscal Year 2013.

lexicon pharmaceuticals inc (LX3) Key Developments

Lexicon Mulls Acquisitions

Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX) wil consider acquisitions. Lexicon Pharmaceuticals announced it has priced its offering at $80 million. Lexicon may also use a portion of the net proceeds to acquire or invest in complementary products and technologies or for general corporate purposes.

Lexicon Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 09:20 AM

Lexicon Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 09:20 AM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.

Lexicon Mulls Acquisitions

Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX) is looking for acquisition opportunities. Lexicon announces proposed convertible senior notes offering and may also use a portion of the net proceeds to acquire or invest in complementary products and technologies or for general corporate purposes.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LX3:GR €0.80 EUR +0.077

LX3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $44.23 USD +0.42
Boston Scientific Corp $13.12 USD +0.175
CR Bard Inc $167.56 USD +1.06
Johnson & Johnson $106.81 USD -1.05
Medtronic Inc $72.81 USD +0.315
View Industry Companies
 

Industry Analysis

LX3

Industry Average

Valuation LX3 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 175.8x
Price/Book 6.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 147.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LEXICON PHARMACEUTICALS INC, please visit www.lexpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.